Gastroenterology

Gastroenterology

Volume 111, Issue 6, December 1996, Pages 1576-1586
Gastroenterology

Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis

https://doi.org/10.1016/S0016-5085(96)70020-3Get rights and content

Abstract

BACKGROUND & AIMS: Approximately 13% of patients with chronic hepatitis D virus (HDV) infection have liver-kidney microsomal antibodies type 3 (LKM-3) directed against family 1 uridine 5'-diphosphate-glucuronosyl- transferases (UGT-1). The aim of this study was to characterize the prevalence and specificity of LKM-3 by recombinant antigen testing systems. METHODS: Enzyme-linked immunosorbent assay (ELISA) and Western blot were performed using baculovirus-generated human UGT-1.1 and -1.6 and rabbit UGT-1.6. Sera from patients with HDV (n = 50), autoimmune hepatitis (AIH) type 2 (n = 50), hepatitis B virus (n = 26), hepatitis C virus (HCV) (n = 25), and LKM-1 autoantibody-positive HCV (n = 14) and sera from normal controls (n = 50) and italian patients with HDV and known LKM-3 autoantibodies were studied. RESULTS: Six percent of patients with HDV from Germany and 8% of patients with type 2 AIH had LKM-3. Sera from italian patients with HDV and patients with AIH type 2 recognized all three recombinant UGT-1. HDV sera from Germany selectively recognized human UGT-1. LKM-3 titers were lower in HDV than in AIH. One patient with AIH had LKM-3 as the only marker of AIH. CONCLUSIONS: This study indicates a molecular target and titer difference of LKM-3 autoantibodies in German subjects with HDV and AIH. It also suggests a geographic target and titer difference of LKM-3 in HDV. LKM-3 are identified as a rare and previously undescribed independent marker of AIH. (Gastroenterology 1996 Dec;111(6):1576-86)

References (0)

Cited by (89)

  • Autoimmune serology testing in clinical practice: An updated roadmap for the diagnosis of autoimmune hepatitis

    2023, European Journal of Internal Medicine
    Citation Excerpt :

    Although anti-LKM3 antibodies have been initially described in up to 13% of patients with chronic hepatitis delta [52], they have also been reported in about 5–10% of AIH-2 patients [48,53]. The major target-autoantigens of anti-LKM3 are members of the family 1 uridine diphosphate glucuronosyl-transferases (Table 2) [53]. Anti-LC1 antibodies are detected in about one-third of AIH-2 patients (coexistence with anti-LKM1 in approximately 50% of cases) [18,21,22,54,55].

  • Hepatitis

    2019, The Autoimmune Diseases
  • The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview

    2018, Journal of Autoimmunity
    Citation Excerpt :

    Anti-LKM3 was first reported by Rizzetto's group in association with chronic hepatitis delta infection, where it is found in some 13% of patients [104]. It stains hepatocyte cytoplasm and proximal renal tubules of human and primate tissue sections, thus hampering its testing in clinical practice, although it has been described in up to 19% of AIH type 2 patients, at times as the only serological marker [105–107]. The target antigen is family 1 uridine 5′-diphosphate glucuronosyltransferase (UGT-1) [106].

  • Cutting edge issues in autoimmune hepatitis

    2016, Journal of Autoimmunity
View all citing articles on Scopus
View full text